Sigilon Therapeutics Inc. (SGTX): Price and Financial Metrics

Sigilon Therapeutics Inc. (SGTX): $0.72

0.02 (+3.37%)

POWR Rating

Component Grades













Add SGTX to Watchlist
Sign Up

Industry: Biotech



in industry

SGTX Stock Summary

  • With a market capitalization of $22,719,716, SIGILON THERAPEUTICS INC has a greater market value than merely 7.33% of US stocks.
  • SIGILON THERAPEUTICS INC's stock had its IPO on December 4, 2020, making it an older stock than just 9.81% of US equities in our set.
  • In terms of volatility of its share price, SGTX is more volatile than 87.11% of stocks we're observing.
  • Stocks that are quantitatively similar to SGTX, based on their financial statements, market capitalization, and price volatility, are SQZ, SLDB, SURF, IKNA, and LVTX.
  • SGTX's SEC filings can be seen here. And to visit SIGILON THERAPEUTICS INC's official web site, go to

SGTX Valuation Summary

  • SGTX's EV/EBIT ratio is -0.4; this is 104.04% lower than that of the median Healthcare stock.
  • SGTX's EV/EBIT ratio has moved up 17.8 over the prior 26 months.

Below are key valuation metrics over time for SGTX.

Stock Date P/S P/B P/E EV/EBIT
SGTX 2023-01-20 2.0 0.5 -0.4 -0.4
SGTX 2023-01-19 1.7 0.5 -0.4 -0.3
SGTX 2023-01-18 1.4 0.4 -0.3 -0.3
SGTX 2023-01-17 1.1 0.3 -0.2 -0.2
SGTX 2023-01-13 1.2 0.3 -0.3 -0.2
SGTX 2023-01-12 1.0 0.3 -0.2 -0.2

SGTX Price Target

For more insight on analysts targets of SGTX, see our SGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.75 Average Broker Recommendation 1.38 (Strong Buy)

SGTX Stock Price Chart Interactive Chart >

Price chart for SGTX

SGTX Price/Volume Stats

Current price $0.72 52-week high $2.08
Prev. close $0.70 52-week low $0.29
Day low $0.69 Volume 70,919
Day high $0.74 Avg. volume 652,011
50-day MA $0.43 Dividend yield N/A
200-day MA $0.67 Market Cap 23.49M

Sigilon Therapeutics Inc. (SGTX) Company Bio

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

SGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

SGTX Latest Social Stream

Loading social stream, please wait...

View Full SGTX Social Stream

Latest SGTX News From Around the Web

Below are the latest news stories about SIGILON THERAPEUTICS INC that investors may wish to consider to help them evaluate SGTX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with an overview of the biggest pre-market stock movers traders will want to keep an eye on!

William White on InvestorPlace | January 19, 2023

Sigilon Therapeutics Third Quarter 2022 Earnings: Beats Expectations

Sigilon Therapeutics ( NASDAQ:SGTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.25m (up 118% from...

Yahoo | November 12, 2022

Sigilon Therapeutics, Inc. (SGTX) Reports Q3 Loss, Tops Revenue Estimates

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 37.21% and 73.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the MPS-1 program, with plans to initiate IND-enabling studies in the second half of 2023 CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop fu

Yahoo | November 10, 2022

Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2022

Read More 'SGTX' Stories Here

SGTX Price Returns

1-mo 105.71%
3-mo 49.69%
6-mo -14.11%
1-year -63.08%
3-year N/A
5-year N/A
YTD 105.71%
2022 -87.32%
2021 -94.25%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7156 seconds.